IGM Biosciences is a privately held biotechnology company that is focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. Since 2010, IGM has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies, and IGM believes it has the most advanced research and development program focused on engineered IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent advantages may provide superior performance, as compared to IgG antibodies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/09/19 | $102,000,000 | Series C |
Haldor Topsoe Holding A/S Janus Henderson Investors Redmile Group Vivo Capital | undisclosed |
